Pfizer-BioNTech’s COVID-19 vaccine is proven to be 100% effective in adolescents between the ages of 12 and 15, based on the results of a phase 3 trial of 2,260 individuals, as reported by both companies on Wednesday.
The improvement of those affected by persistent COVID after being vaccinated opens a new scientific unknown
The trial has shown “100% efficacy and robust antibody responses, superior to those previously reported with participants aged 16 to 25, and was well tolerated,” according to a statement from BioNTech, the German pharmaceutical partner of the US. Pfizer.
Albert Bourla, president and CEO of Pfizer, said that the intention is to submit an application for authorization to the US agency FDA and other regulatory bodies in order to start vaccinating in that age group “before the start of the next school year. “, although for now the results have not been reviewed by other independent researchers or published in scientific journals.
The trial was carried out with adolescents in the United States between the ages of 12 and 15 years and in it, 18 cases of Covid 19 were detected in the placebo group compared to none in the vaccinated group.
This shows “strong immunogenicity in a subgroup of adolescents one month after the second dose,” according to the statement from both pharmaceutical companies, which indicates that the observed side effects were similar to those detected with the trial in the group between 16 and 25 years.
BioNTech Co-Founder and CEO Ugus Sahin stated that the trial results are “very encouraging given the trends we have seen in recent weeks in the spread of variant B.1.1.7”, initially detected in the UK. .
The BioNTech and Pfizer vaccine was the first formulation against coronavirus authorized in the European Union, at the end of last December, and has shown more than 95% effectiveness.
When announcing its results on Monday, the German pharmaceutical company explained that, together with Pfizer, it plans to increase the production of its vaccine against COVID-19 this year from the 2 billion doses initially planned to 2.5 billion in order to respond to the increase. Of demand.
Until March 23, BioNTech and Pfizer supplied more than 200 million doses of its BNT162b2 vaccine worldwide and by the end of the year they will add more than 1.4 billion, according to the orders received so far, although there are already talks for a supply additional.
With information from EFE.